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ABSTRACT 
Kurtis Matthew Host: Interaction of Kaposi’s Sarcoma-associated Herpesvirus with the Host 
Immune System 
(Under the direction of Blossom Damania)  
 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent for three 
human malignancies; Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and 
multicentric Castleman’s disease (MCD). KSHV-related diseases primarily manifest in 
immunocompromised hosts such as HIV positive patients, iatrogenic immune suppression, 
and geriatric populations. However, some subtypes of KS exist in the absence of obvious 
immune deficiency and remain poorly understood. KS is the leading cause of cancer in the 
sub-Saharan African nation of Malawi. Therefore, we sought to characterize the current 
clinical burden of KS in Lilongwe, Malawi, the capital city. We found that the majority of 
KS cases were associated with HIV. Interestingly, 9% of cases were in HIV naïve patients, 
suggesting a significant burden of the endemic subtype of KS. Our results suggest a needed 
emphasis for endemic KS research, a poorly understood subtype, as it represents a significant 
proportion of Malawi’s leading cancer.  
KSHV is recognized by the immune system, however, it encodes multiple 
mechanisms for thwarting effective immune responses. One mechanism implicated in 
escaping immune clearance is programmed death ligand 1 (PD-L1) overexpression. PD-L1 is 
a co-inhibitory molecule which interacts with the programmed death 1 (PD-1) receptor on T 
cells. PD-1:PD-L1 engagement blocks T cell receptor (TCR) signaling resulting in reduced T 
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cell activation. Chronic PD-1:PD-L1 ligation results in T cell exhaustion. Tumor cells have 
been found to utilize PD-L1 to escape immune elimination. Current treatment targeting PD-
L1 in certain cancer types is showing clinical efficacy. Therefore, we sought to determine if 
KSHV could increase PD-L1 expression. We found that KSHV is able to increase PD-L1 
expression in human monocytes following infection. In addition, the cytokine profile showed 
a proinflammatory milieu. Our report is the first to show direct KSHV increase of PD-L1 
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 CHAPTER 1. INTRODUCTION 
INTRODUCTION 
In completion of my graduate studies under the guidance of Dr. Blossom Damania, 
the following dissertation will examine the interaction of Kaposi’s sarcoma-associated 
herpesvirus (KSHV) with the host immune system. First, the current understanding of KSHV 
disease and immune checkpoints will be discussed to establish necessary background for my 
dissertation research. Second, the clinical burden of KS in a KSHV endemic area will be 
analyzed (1). Third, KSHV’s ability to modulate the expression of the immune checkpoint 
molecule, programmed death ligand 1 (PD-L1), on monocytes will be discussed (2). Finally, 
I will discuss my findings in the context of a bigger picture as well as future directions for 
my projects.  
KSHV, also known as human herpesvirus-8 (HHV8), is one of seven oncogenic 
viruses that are responsible for an estimated 15-20% of human cancers worldwide (3, 4). In 
particular, KSHV is associated with the endothelial cell malignancy, Kaposi’s sarcoma (KS), 
and the B cell proliferative disorders, primary effusion lymphoma (PEL) and multicentric 
Castleman’s disease (MCD) (5-7). KSHV-related diseases primarily manifest in 
immunocompromised hosts such as HIV positive patients, iatrogenic immune suppression, 
and geriatric populations, suggesting that the immune system is important in controlling 
KSHV-mediated diseases (3). As such, it is of the utmost importance to understand the 
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interaction of KSHV with the host immune system. My findings, as detailed in this 
dissertation, have added significantly to our understanding between the interaction of KSHV 
and the host immune system. First, I was able to quantify the current burden of KS in a 
highly endemic region, highlighting the further need to research KS development in the 
absence of HIV co-infection (1).  My study was a small, but necessary, step in understanding 
the current burden of KS and in guiding future resource allocation in a severely resource-
restricted setting. Next, I was the first to show that KSHV infection results in PD-L1 
induction in monocytes (2). Given the current efficacy of PD-L1/PD-1 blockade therapies, 
my results may provide a rationale for treating KSHV-mediated diseases with PD-1:PD-L1 
blockade therapy. The following sections within Chapter One provide the necessary 
background for my projects.  
KSHV ASSOCIATED CANCERS 
Seven human oncogenic viruses; KSHV, Epstein Barr virus (EBV), human 
papillomavirus (HPV), Hepatitis C virus (HCV), Hepatitis B virus (HBV), Merkel cell 
polyomavirus (MCV), and human T-lymphotropic virus (HTLV), are associated with an 
estimated 15-20% of human cancers worldwide (3, 4). KSHV is the etiological agent of three 
human cancers; the endothelial cell malignancy, KS, and the B cell proliferative disorders 
PEL and MCD (5-7). KSHV establishes a mostly quiescent lifelong infection which can 
progress into malignancy. Progression of KSHV infection into tumorigenesis is often linked 
to a compromise of the host immune system, although patients with ostensibly intact immune 
function can develop KSHV-associated malignancies as well. Immune compromised 
populations at high risk for KSHV-associated diseases are HIV- infected patients and solid 
organ transplant recipients. In the eighties, the outbreak of HIV lead to an explosion in the 
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number of cases of KS, eventually leading to the discovery of KSHV in 1994 (5).  However, 
as mentioned above, KS can occur in seemingly healthy individuals including in people 
living in KSHV endemic regions such as the Mediterranean and sub-Saharan Africa. KSHV 
is the etiological agent among KS, PEL, and MCD, yet no curative nor preventative 
treatment has been found to date. 
KS was first described in 1872 by Moritz Kaposi in elderly Mediterranean men (8). 
Since then, 4 general subtypes of KS have been described; AIDS (epidemic), African 
(endemic), iatrogenic, and classic KS, based on clinical characteristics and co-factors present 
(9). AIDS-KS follows HIV and KSHV co-infection, and can occur in patients at varying 
levels of CD4 T cell counts, although incidence increases as CD4 count decreases (10). 
Increasing control of HIV infections through early diagnostic tests and antiretroviral therapy 
(ART) was predicted to decrease KS incidence, however, rates have remained higher than 
expected (11). Interestingly, infection with HIV in the pre-ART era increased the chance of 
developing KS by 20,000 fold whereas any other type of immune suppression only increased 
a patient’s risk by 300 fold (12). There may be viral synergism that is as of yet 
underappreciated between HIV and KSHV. For example, HIV-1 trans-activating (TAT) 
protein has been found to increase cell susceptibility to KSHV infection and stimulate KSHV 
reactivation from latency (13, 14). Unlike AIDS-KS, Endemic (African) KS does not have a 
clear precipitating factor aside from KSHV infection. endemic KS presents in both the young 
and old, and is prevalent primarily in sub-Saharan Africa (1, 15). Previous work has 
postulated links between endemic KS with volcanic soils, African natural products, and 
genetic predisposition (16-18). Iatrogenic KS is seen in transplant recipients where immune 
suppressing drugs are utilized to avoid solid organ rejection. Finally, classic KS is the disease 
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described by Moritz Kaposi which afflicts geriatric patients of Mediterranean or Jewish 
decent (8). Presentation and prognosis vary among the subtypes ranging from indolent 
lesions in the lower extremities in classic KS to aggressive visceral involvement in some 
cases of endemic KS (19). Regardless of subtype, the tumor tissue is similar histologically, 
being primarily composed of endothelial cell derived spindle cells harboring latent KSHV 
(3). The tumor microenvironment is characterized by high amounts of leaky vasculature and 
infiltration with multiple immune cell types including monocytes (3, 20). Interestingly, KS 
seems to progress in the setting of inflammation (21, 22). Specifically, KS lesions can 
paradoxically worsen following bouts of immune reconstitution inflammatory syndrome 
(IRIS), a syndrome characterized by high amounts of inflammation following ART initiation 
(23). Upon presentation of KS, if the immune suppression can be removed (cessation of 
iatrogenic suppression or ART administration, etc) KS may regress (24, 25). First line 
treatment varies with extent and location of KS lesions. Local surgery or radiotherapy can 
result in response, however, KS lesions may develop in untreated regions. Systemic 
chemotherapy can be effective but is not curative as the underlying KSHV infection is never 
fully cleared.  
PEL is a monoclonal B cell lymphoproliferative disease associated with KSHV (6, 
26). PEL cells harbor latent KSHV and are generally derived from cells within the post 
germinal center but pre-terminal stage prior to plasma cell differentiation (27). In addition to 
KSHV, EBV is common in PEL cells (28). PEL presents as effusions in body cavities 
including pleural, peritoneal, and pericardial cavities, with rare involvement of joint and 
meningeal spaces with no central tumor mass typically present within the body (29). 
Symptoms depend on the area of the body containing the effusions. PEL is seen almost 
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exclusively in immunodeficient patients, typically following transplant or HIV infection (26). 
PEL is very aggressive with median survival being 3-4 months without treatment and 6 
months with treatment (26).  
MCD is a polyclonal plasma cell or mixed variant B cell lymphoproliferative disease 
associated with KSHV (7, 30). Presentation can be variable with the overall clinical picture 
of an inflammatory illness. Patients can present with generalized peripheral 
lymphadenopathy, hepatosplenomegaly, frequent fevers, and night sweats. MCD can be 
KSHV-negative along with unilateral Castleman’s disease which also presents with similar 
symptoms. Castleman’s disease in all forms is heavily driven by excessive interleukin 6 (IL-
6) signaling (30). Current therapies for unilateral Castleman’s and KSHV-negative MCD 
involves IL-6 neutralizing antibodies. KSHV encodes a viral homologue to human IL-6, 
named vIL-6 (3). Human IL-6 signals through gp80 and gp130 components complexed 
together, whereas, vIL-6 is able to signal through just gp130 (3). Expression of vIL-6 is 
primarily present during the lytic cycle, though low levels are present in latent infection. A 
prognostic marker for MCD is the level of lytic activity as assessed by levels of circulating 
KSHV genomes (31). Similar to other KSHV-mediated cancers, KSHV associated MCD 
primarily presents in the setting of HIV infection. Furthermore, MCD is often accompanied 
by KS in many patients (32). As opposed to PEL, MCD B cells retain CD20 and often lack 
EBV co-infection. Treatment for KSHV-associated MCD consists of rituximab, an anti-
CD20 antibody, and ganciclovir to inhibit KSHV lytic replication (33). Prognosis can vary, 
however MCD is generally aggressive in HIV-infected individuals as the median survival 
time for patients was 8 and 14 months in two different studies (32, 34).  
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KAPOSI’S SARCOMA-ASSOCIATED HERPESVIRUS, HHV-8 
KSHV, or HHV-8, is the most recently discovered human herpesvirus to date (5). 
Within the herpesviridae, KSHV is a gammaherpesvirus (3) as is EBV (35). KSHV is an 
enveloped, double stranded DNA (~180 kbp) virus tropic for endothelial cells, epithelial 
cells, B cells, dendritic cells, macrophages, and monocytes (3). The KSHV virion contains 
viral genomic DNA, a capsid, a proteinaceous layer termed the tegument, and finally an 
envelope (Fig 1.1) (3). The KSHV viral glycoproteins gB, gH, open reading frame 4 (ORF4) 
and gpK8.1A help to attach the virion to heparin sulfate moieties on the cell surface (Fig 1.1) 
(36). Furthermore, glycoprotein gB interacts with integrin components α3 and β1 to attach 
the virion to the cell surface and initiate viral entry (36). Additional studies have found roles 
for integrins αVβ3 and αVβ5, dendritic cell specific intracellular adhesion molecule–3 
(ICAM-3) grabbing nonintegrin (DC-SIGN), the transmembrane light chain of human 
cystine/glutamate exchange transporter system x-c (xCT), and Ephrin type-A receptor 2 
(EphA2) in virion attachment and entry (Fig 1.1) (37-43).The virion enters primarily through 
endocytosis (Fig 1.1) (36). In human embryonic kidney cells 293 (HEK 293) and endothelial 
cells, the resultant endocytic vesicles are then acidified (44, 45). The viral envelope fuses 
with the endosome and the tegument is exposed to the cell cytosol (Fig 1.1) (36, 45, 46). 
Following uncoating, the intact capsid structure is transported to the nucleus along 
microtubules via dynein motor proteins where the genomic material is injected (Fig 1.1) (47). 
Similar to other herpesviruses, the KSHV lifecycle contains both a lytic and latent phase 
(48). Upon nuclear entry of a target cell, KSHV expresses a limited subset of its lytic genes 
in the first 24 hours postinfection which is followed by latent gene expression (49). The virus 
subsides into a latent state that will be its default state for the vast majority of the host’s 
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lifespan (49). During the latent phase, a small subset of ORFs are expressed and the KSHV 
genome is replicated by the host DNA replication machinery to ensure the genome is passed 
to the daughter cells (48). Spontaneous reactivation results in a switch from the latent to lytic 
phase, often without apparent symptoms in patients. Full lytic replication is characterized by 
expression of the vast majority of the greater than 84 viral ORFs and production of infectious 
progeny (48). As with all herpesviruses, KSHV infection lasts the lifetime of the host. Thus it 
is apparent that the host immune system successfully recognizes KSHV but is unable to clear 
all viral reservoirs following primary infection. KSHV-mediated pathology is most often 
observed in the context of immune system disruption, suggesting that immune control of 
KSHV is important in preventing downstream pathology.  
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Figure 1.1. Kaposi’s sarcoma–associated herpesvirus (KSHV) entry. Depicted are virion 
binding, attachment, and entry into the host cell. The different stages of KSHV entry are 
highlighted. Once the viral genome enters the nucleus, the decision to enter the latent or lytic 
phase of the life cycle is made. Adapted from Damania & Cesarman, Fields Virology, 2013. 
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KSHV seropositivity varies widely around the globe (50). Our current understanding 
of seropositivity is limited due to a lack of a gold standard for determining KSHV infection. 
Although antibodies are generated to the virus and circulating viral genomes can be detected, 
the levels of both change drastically over the course of infection. With these limitations in 
mind, a brief summary of our current understanding of KSHV seropositivity is described 
below.  
KS was first described in men of Mediterranean and Jewish heritage in 1872 (8). The 
Mediterranean region has remained positive in the intervening years ranging from 19-35% 
KSHV seroprevalance (51). Although high in seroprevalance, classic KS in the region has 
remained a fairly rare neoplasm, afflicting only elderly male patients. In contrast, KS is a 
common tumor in Africa (16, 19). Historically the disease tended to be present in populations 
of sub-Saharan Africa (16, 19, 52). Central and Eastern Africa have extremely high 
prevalence, with around 50% positivity by adulthood in some regions (50, 53). KS present in 
Africa is distinct from classic KS as it tends to be more aggressive and present in younger 
patients with less of a sex bias (19). Following the HIV epidemic, KS in sub-Saharan Africa 
was greatly increased as HIV prevalence spread across the region. KS is currently the leading 
cause of cancer in much of sub-Saharan Africa, with the majority of cases being AIDS-KS 
(3). In the United States, the HIV outbreak increased the burden of KS cases which presented 
in young, homosexual men (54, 55). These cases became the earliest heralds of the HIV 
epidemic. Although studies vary in the exact seropositivity rate and assay used, the estimates 
are between 1-4% of the general population with one study estimating up to 30% in some 
blood donor groups (56-58). These estimates spike when examining men who have sex with 
men (MSM) groups as previous studies have shown a stable 26% seropositivity rate in a San 
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Francisco cohort (59). Though KSHV related disease is rarely seen in Asian countries, 
several studies have shown high rates of seropositivity in northern Thailand (24%), the 
Miyako Islands in Japan (15%) and Taiwan (23%) (60-62). South American countries also 
lack a heavy KS burden but show moderate seropositivity with 16% in urban communities of 
northern Brazil (63). Interestingly, a group of Brazilian Amerindians previously uncontacted 
by the outside world was shown to have 53% seropositivity (64). The transmission profile of 
KSHV differs by region. In well developed areas of the world, the transmission is related 
primarily to sexual contact. In underdeveloped areas, the transmission is often horizontal 
within families. This is suggested by studies showing that a large proportion of patients are 
KSHV positive prior to puberty in underdeveloped areas as opposed to increased risk 
following increased sexual partners in well developed countries (50, 53). The current route of 
KSHV transmission is not definitively known, although studies have found KSHV within 
semen, breast milk, blood, and saliva (65, 66). The levels in saliva are found at 2.5 times 
higher amounts than in semen, and explain both the sexual and horizontal transmission of 
KSHV (65). Initial infection with KSHV has been described to have varying symptoms 
including maculopapular rash and fever in children and lymphadenopathy in MSM (67-69). 
These symptoms are not uniform and often don’t require hospitalization, as such little is 
known about primary infection with KSHV. Much is still left to learn about the virus, and 
better serological tests and epidemiology studies should provide a clearer picture of the 
current burden of KSHV globally.  
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KSHV IMMUNE MODULATION 
KSHV is recognized by both the innate and adaptive components of the host immune 
system, yet establishes lifelong infection. Innate immunity is a primordial defense 
mechanism that consists of pathogen recognition receptors (PRRs) designed to recognize 
pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns 
(DAMPs) and mount a response. PRRs include Toll-like receptors (TLRs), RIG-I like 
receptors (RLRs), Nucleotide-binding oligomerization domain-like receptors (NLRs), AIM2-
like receptors (ALRs), and DNA sensing pathways such as the cyclic GMP-AMP synthase 
(cGAS)- stimulator of interferon genes (STING) pathway (70). These PRRs recognize a wide 
range of motifs, ranging from nucleic acid to protein. KSHV is a double stranded DNA 
(dsDNA) virus, yet stimulates at least one receptor in each of the aforementioned PRR 
categories. KSHV is sensed by TLR3, 4, and 9 (71-73). KSHV RNA, envelope components, 
and DNA moieties are likely activating TLR3, 4, and 9 respectively (71-73). Next, RLRs 
sense foreign RNA motifs such as double stranded RNA (dsRNA). Although a dsDNA virus, 
KSHV generates dsRNA as part of its lifecycle (74). Accordingly, KSHV activates and is 
inhibited by RLRs such as retinoic acid-inducible gene I (RIG-I) (74, 75). NLR’s stimulate 
immune response to PAMPs associated with bacterial pathogens and both DNA and RNA 
viruses (76, 77). KSHV infection activates NACHT, LRR and PYD domains-containing 
protein (NLRP) 1 and 3 (78). ALRs can sense intracellular DNA and stimulate an immune 
response (77). The ALR molecule IFI16 can detect both primary and latent KSHV infection 
(79, 80). Finally, in addition to ALRs, the host cell utilizes the cGAS/STING pathway to 
sense cytosolic DNA. KSHV primary infection and reactivation from latency are sensed by 
the cGAS-STING pathway (81-83). KSHV infection is vulnerable to PRR detection 
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however, as will be discussed below KSHV is still able to overcome immune detection to 
successfully establish infection.  
Given the multitude of ways that the host immune system can detect KSHV, it is not 
surprising that the virus carries with it an equally diverse array of interference molecules (84, 
85). Here I will discuss three key areas that KSHV utilizes for innate immune modulation. 
First, KSHV packages immune evasion proteins into its tegument to facilitate immune 
evasion prior to viral gene expression in the newly infected cell. Next, KSHV transitions 
between lytic and latent phases and is able to use the proteins critical in the shift to inhibit 
innate immune response during reactivation from or establishment of latency.  Finally, 
KSHV encodes viral homologues of multiple cellular genes and uses these to interrupt 
normal cellular signaling during various steps of its lifecycle. Thus from initial viral entry to 
long term infection and reactivation, KSHV encodes a wide array of innate immune escape 
mechanisms.  
First, the KSHV virion tegument is exposed to the host cell cytoplasm upon initial 
entry (Fig 1.1) and contains the ORFs 21, 33, 45, 63, 64, and 75 (86). Of note, ORF45, 63, 
and 64 are able to counteract innate immune signaling. KSHV ORF45 can inhibit interferon 
regulatory factor 7 (IRF7) phosphorylation, a downstream signaling component of innate 
sensing, thereby decoupling a multitude of PRR signaling processes (87, 88). ORF63 inhibits 
the function of NLR proteins NLRP1 and NLRP3 to limit NLR activation of host 
inflammasomes during KSHV infection (78). ORF64 can deubiquinate TRIM25, a 
downstream signaling component of the RLR, RIG-I, to partially alleviate the inhibition of 
KSHV lytic gene expression through RIG-I-mediated interferon signaling (75, 89). Thus, 
KSHV is able to counteract PRR activation and downstream signaling prior to viral gene 
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expression within the newly infected cell. KSHV encodes a lytic switch protein (ORF50) to 
begin viral reactivation and a latency associated nuclear antigen (LANA) which is necessary 
for the virus to establish latency. As the virus reactivates from latency into the lytic phase, 
ORF50 is highly expressed and induces transcriptional upregulation of lytic genes. During 
lytic reactivation, the vast majority of viral ORFs will be expressed and infectious progeny 
produced. As such, lytic phase presents the host cell with high amounts of targets for host 
cell PRRs. To combat this KSHV ORF50 induces the degradation of TLR3, myeloid 
differentiation primary response 88 (MyD88) (the common adaptor protein for all TLRs, 
except TLR3), and IRF7 (90-93) thereby reducing both a KSHV sensing PRR and 
downstream signaling components. Outside of lytic infection, latency is a mostly quiescent 
state where minimal viral ORFs are expressed. During the initial establishment of latency, 
LANA can counteract ORF50 transcription and thereby decrease lytic gene expression. 
LANA is then expressed throughout the entire lifespan of KSHV infection. Cytoplasmic 
isoforms of LANA bind to cGAS and inhibit cGAS-STING downstream signaling through 
Tank binding kinase 1 (TBK1) and IRF3 to inhibit host cell sensing of KSHV DNA (83). 
Further, LANA binds DNA within the nucleus to inhibit interferon β (IFNβ) transcription 
and IFNγ inducible gene transcription (94, 95). Thus, both ORF50 and LANA are able to 
either degrade or inhibit a PRR capable of sensing KSHV and downstream signaling 
molecules for both intra- and intercellular signaling. Finally, KSHV encodes four viral 
homologues of host IRF3 and 7, termed viral interferon regulatory factor (vIRF) 1, 2, 3, and 
4 which interfere with innate signaling (96). These molecules have been implicated in 
inhibiting downstream signaling of TLR3, mitochondrial antiviral-signaling protein (MAVS) 
(a downstream signaling component of RLRs), and cGAS-STING during either KSHV 
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primary infection or reactivation from latency (81, 97, 98). Further, vIRF molecules can 
interfere with TLR4 transcription and IFN stimulated genes such as ISG15 function (73, 99). 
Thus, vIRFs are able to interfere with KSHV detection and subsequent interferon response. 
The constant push and pull between KSHV and the innate immune system has generated a 
constant arms race between virus and host, generating a wide array of sensing and 
interference mechanisms. 
In addition to innate immunity, humans have an adaptive system which mounts 
specific responses to pathogens. Infectious pathogens are recognized via their antigens. 
These antigens can then be used by immune cells to better recognize the pathogen or infected 
cells harboring the pathogen. Further, antibody can be produced against an antigen. Once 
antigen is recognized, immune effector cells such as T cells can directly kill cells presenting 
antigen from an intracellular pathogen. Antibody and antigen specific T cells are generated 
during KSHV infection (62, 100-102). However, KSHV is able to modulate many steps of 
adaptive immunity to escape elimination.  
As detailed above, initial KSHV infection stimulates an innate immune response. 
This response can upregulate antigen presenting machinery, e.g. major histocompatibility 
complex (MHC) I and II, on the infected cell surface. The MHC complexes can then present 
pathogen associated antigen to alert immune cells to the presence of the pathogen. Once 
alerted, effector cells such as CD8+ T cells can directly kill the infected cell. To effectively 
hide from this detection, KSHV is able to inhibit antigen display on the surface of the 
infected cell via MHC class I downregulation via transcriptional inhibition by vIRF1 and by 
decreased surface expression of MHC via viral proteins K3 and K5 (103-105). KSHV further 
inhibits antigen display by inhibiting MHC class II transcription via vIRF3 (106). 
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Downregulation of MHC allows less antigen presentation but is a common pathogen escape 
mechanism. As such, the host immune system scans for the absence of MHC complexes 
which can lead to direct cell killing via Natural killer (NK) cells. KSHV avoids NK cell 
targeting through K5 induced internalization of NKG2D and NKp80 ligands, thereby 
avoiding NK cell cytotoxicity (107). Although KSHV can reduce antigen presentation, it 
can’t completely avoid it. Once antigen is presented, CD8+ T cells engage the antigen loaded 
MHC complex on the infected cell with the T cell receptor (TCR) and wait for a second 
signal prior to response. The T cells can receive either stimulatory or inhibitory co-signals 
following TCR ligation of MHC. Stimulatory signals can result in direct cell killing and 
inhibitory signals can result in antigen tolerance. As such KSHV modulates co-stimulatory 
signaling molecules to avoid T cell mediated destruction. The KSHV protein K5 is able to 
downregulate the surface expression of the CD86 costimulatory molecule, a protein which 
induces T cell-mediated killing via binding of CD28 on T cells (105). Furthermore, KSHV 
infection of monocytes induces expression of PD-L1, a co-inhibitory molecule (2). Thus, 
KSHV is able to reduce stimulatory proteins and increase inhibitory co-signaling molecules 
to escape T cell cytotoxicity. Finally, in effective immune responses, a pathogen is detected 
and immune cells are activated and recruited to quickly eliminate the infection through 
signaling molecules termed cytokines and chemokines. KSHV is able to modulate both the 
activation and recruitment of a wide array of immune cell types to avoid viral clearance. 
KSHV vCD200, a viral homologue of CD200, surface expression inhibits the activation of 
neutrophils, basophils, and macrophages to keep these immune cell types from clearing the 
viral reservoirs in infected cells (108, 109). The KSHV cytokine homologue viral 
macrophage inflammatory protein II (vMIP-II) inhibits monocyte and NK cell chemotaxis 
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but attracts T helper 2 (Th2) T cells (110-112). Further, a KSHV cytokine homologue vMIP-
III also attracts Th2 T cells (113). KS tumors are highly infiltrated by lymphocytes and can 
progress in the setting of inflammation (20, 21).Thus KSHV is able to modulate recruitment 
of specific immune cell types, which may play an important role in KS tumor progression 
(20, 21).  
IMMUNE CHECKPOINT THERAPY 
The host immune system is a surveillance system built to recognize and eliminate 
anything that is deemed non-self. Whenever the immune response is triggered, a 
counterbalancing brake must be applied to avoid collateral damage. When T cells recognize 
presented antigen via the TCR, immune checkpoint molecules give direction to the T cell 
response either stimulating an inflammatory response or generating tolerance of the antigen 
(114, 115). As malignant cells aberrantly grow, they accumulate differences that can be 
recognized as non-self antigen by the immune system (116). Tumor modulation of immune 
checkpoint molecules can skew T cell response for the benefit of the tumor tissue. If the 
immune system begins recognizing a tumor, an influx of lymphocytes, including T cells, 
infiltrates the microenvironment (115, 117). Following infiltration, proinflammatory 
cytokines including IFNγ can be secreted (115). The expression of IFNγ results in 
upregulation of inhibitory immune checkpoint molecules such as PD-L1, which then masks 
the tumor from T cell attack. If this expression continues chronically, T cells will become 
exhausted. Thus, the tumor has effectively escaped a healthy immune response by induction 
of PD-L1. In place of transient PD-L1 induction, some tumors have genetic changes which 
result in constitutive expression of inhibitory molecules or otherwise allow escape from 
immune detection such as change of antigen presentation or manipulation of cytokine 
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expression (117). Overexpression of inhibitory markers masks the tumor tissue from the 
immune system. Thus, immune checkpoint therapy is aimed at removing T cell inhibitory 
signals and in some cases adding T cell agonists to restore proper response (114, 115).  
Immune checkpoint therapy began with the discovery of the cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) molecule. Upon activation in T cells, CTLA-4 is upregulated 
on the surface of the cell. T cell stimulation occurs by TCR ligation with CD28 co-
stimulation. CTLA-4 and CD28 share the same ligands; CD80 and CD86, however, CTLA-4 
has higher affinity for both and competes for binding (118). Thus, when CTLA-4 occupies 
CD80 or CD86 in place of CD28, no downstream stimulatory signal is transmitted following 
TCR ligation. CTLA-4 ligation has been reported to propagate negative signaling cascades, 
however, a consensus for this exact mechanism remain elusive (119). Chronic TCR ligation 
without CD28 co-stimulation results in antigen tolerance. Thus, removal of CTLA-4 allows 
increased T cell stimulation. Antibody against CTLA-4 has shown efficacy in melanoma, 
renal cell carcinoma, prostate cancer, urothelial carcinoma, and ovarian cancer (120-125). In 
addition to CTLA-4, programmed death 1 (PD-1) is an immune checkpoint cell surface 
receptor on activated T cells, which plays a role in T cell mediated peripheral tolerance. 
During TCR ligation, PD-1 interacts with PD-L1 on the target cell, leading to downstream 
uncoupling of stimulatory signals within the T cell. Antibodies to PD-1 and PD-L1 have 
shown efficacy in melanoma, renal cell carcinoma, non-small cell lung cancer, and bladder 
cancer (126-131). Antibodies to CTLA-4 (ipilimumab), PD-1 (pembrolizumab, nivolumab), 
and PD-L1 (atezolizumab, avelumab, durvalumab) have received FDA approval for clinical 
use. CTLA-4 and PD-1 are both inhibitory receptors, but with differing mechanisms. 
Interestingly, combination therapy with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-
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1), is showing efficacy, suggesting that combining differing immune checkpoint inhibitors 
could provide better results, however, these gains also come with higher toxicities in the 
combination therapy versus monotherapy (132, 133). Although much research has been 
performed, we have only begun scratching the surface with current therapies. Other 
inhibitory immune checkpoint targets under current investigation include B- and T-
lymphocyte attenuator (BTLA), V-domain Ig suppressor of T cell activation (VISTA), T-cell 
immunoglobulin and mucin-domain containing-3 (TIM-3), and lymphocyte-activation gene 3 
(LAG3) (134-137). In addition, checkpoint agonists could be important for optimizing T cell 
responses, especially in poorly immunostimulatory tumors. Candidate agonists currently 
being studied include 4-1BB, OX40, glucocorticoid-induced TNFR-related protein (GITR), 
inducible T-cell costimulator (ICOS), and CD40 (138-142). We are just at the very beginning 
stages of applying immune checkpoint therapy against cancer and current positive results in 
the clinic give rise to optimism moving forward.  
PD-L1 REGULATION AND FUNCTION 
Programmed death ligand 1 (PD-L1; B7-H1; CD274) is an immunomodulatory cell 
surface protein which interacts with the Programmed death 1 (PD-1; CD279) receptor on 
activated T, B, myeloid and Natural Killer (NK) cells to induce a co-inhibitory signal (143-
151). PD-L1 is an immune checkpoint molecule that is important in peripheral immune 
tolerance (144, 147, 152-155). PD-L1 can be induced through multiple avenues. First, PD-L1 
is responsive to type I and II IFN signaling with IFNγ being a major inducer (154-158). IFN 
signaling is mediated in part by signal transducer and activator of transcription (STAT) 
phosphorylation, and as such PD-L1 is responsive to STAT 1 and 3 phosphorylation (159-
161). In addition to IFN signaling, stimulation of PRRs such as TLRs and cytokine signaling 
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can result in PD-L1 stimulation (154, 157, 162-168). The mitogen-activated protein kinase 
(MAPK)/Extracellular signal-regulated kinase (ERK) signaling pathway, which is a 
downstream component of some cytokine paracrine signals, has also been shown to induce 
PD-L1 (169). Following cytoplasmic signaling events, the promoter region of PD-L1 
contains elements responsive to nuclear factor-kappa B (NF-κB) and IRF-1 (156, 170). Once 
PD-L1 is transcribed and translated, it is trafficked to the surface of the cell to become active. 
PD-L1 shows varying surface expression kinetics in response to different stimulation with 
IFNγ inducing the most stable duration (154). PD-L1 is inducible through a wide array of 
stimulants, suggesting that it is a commonly used motif to slow down the immune response.  
 Following surface expression of PD-L1, the ligand interacts with its cognate receptor 
PD-1. PD-1 is upregulated on T cells following T cell activation. As activated T cells use 
their TCR to interact with surface presented antigen, there is a co-stimulatory signal which 
informs the T cell of the appropriate response. PD-1 is adjacent to the TCR and receives the 
suppressive signal from PD-L1 (145, 148, 171). Stimulatory signaling through TCR typically 
results in phosphorylation of protein kinase C theta (PKCθ) by zeta-chain-associated protein 
kinase 70 (Zap70)/CD3ζ signalosome. Following PD-1:PD-L1 ligation, the cytoplasmic tail 
of PD-1 recruits Src-homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1) 
and SHP-2 phosphatases where they dephosphorylate Zap70/CD3ζ signalosome, thereby 
inhibiting downstream signaling from the TCR to PKCθ (145, 148, 171).  PD-1:PD-L1 
ligation leads to a general immunosuppressive response including a reduction in direct cell 
killing and reduced secretion of IFNγ and IL-2 (162, 172, 173). Chronic ligation of this axis 




 CHAPTER 2. KAPOSI’S SARCOMA IN MALAWI: A CONTINUED PROBLEM 
FOR HIV-POSITIVE AND HIV-NEGATIVE INDIVIDUALS1 
OVERVIEW 
Kaposi’s sarcoma (KS) is the commonest AIDS defining cancer in Africa. From 2014 
to 2016, 237 KS cases were reported at a national teaching hospital in Malawi, with 9% in 
HIV- individuals, many of whom required chemotherapy. Age distribution and clinical 
characteristics appeared to differ by HIV status. HIV- KS remains poorly understood but 
represents a significant proportion of contemporary KS burden in Malawi, and should be 
included in regional efforts focused on HIV+ populations. 
INTRODUCTION 
Kaposi’s sarcoma (KS) is the leading cancer in much of sub-Saharan Africa (3). HIV 
has resulted in a dramatic increase in KS throughout the region, due to high overlapping 
prevalence of HIV and the etiologic agent of KS, Kaposi’s sarcoma-associated herpesvirus 
(KSHV) (5). KS is divided into four major categories: classical, iatrogenic, AIDS-related, 
and endemic. Endemic KS is the only KS subtype where a specific immune disturbance is 
not readily apparent (15). In Malawi, KS is the leading cancer overall accounting for 34% of 
all malignancies recorded in the national cancer registry (177). In a setting of high KS 
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burden, we sought to describe contemporary burden and characteristics of KS in the HIV-
positive and HIV-negative populations at a national teaching hospital in the capital, 
Lilongwe. 
RESULTS 
We analyzed KS cases from May 2014 until May 2016 in the Kamuzu Central 
Hospital Cancer Registry, which involves active registration of cancer cases across all 
hospital departments using standardized data collection forms. We identified 237 overall KS 
cases, of which 153 were confirmed HIV-positive and 21 confirmed HIV-negative. KS 
diagnoses were histologically confirmed in 39% (92/237) of cases overall, including 33% 
(50/153) of confirmed HIV-positive and 71% (15/21) of confirmed HIV-negative cases. We 
abstracted tumor location and subtype from all confirmed pathology reports. 
  As expected, KS patients were more commonly males regardless of HIV status 
(Table 2.1). Age distribution was significantly different based on HIV status (p = 0.012, 
Fisher’s exact test, see Figure 2.1; Graph of KS age distribution within HIV + and – by 
decade). HIV-positive cases primarily presented during young to mid-adulthood with 68% of 
cases occurring between 20 and 49 years of age. By contrast, HIV-negative cases were more 
evenly distributed among age groups. HIV-positive KS tended to present with disease at 
diverse anatomical sites, whereas HIV-negative KS appeared to primarily present in the 
lower extremities (60%). Similarly, lesion descriptions in pathology reports suggested greater 
lesion heterogeneity among HIV-positive patients, with predominantly plaque or nodular 
lesions among HIV-negative patients (73%). Finally, among patients for whom the primary 
treatment modality was recorded, 49% of HIV-positive patients and 33% of HIV-negative 
patients received chemotherapy. Of note, radiotherapy is not available in Malawi. 
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Figure 2.1. KS Age Range Distribution at Kamuzu Central Hospital. Frequency of each 
age grouping was calculated within HIV + and - categories separately. p = 0.012, Fisher’s 
exact test. 
DISCUSSION 
These findings suggest that despite high HIV prevalence in Malawi, HIV-negative 
endemic KS represents at least 9% of contemporary KS burden at a national teaching 
hospital, with possible differences in presenting characteristics between HIV-positive and 
HIV-negative patients. Despite major investments and research programs in the region 
focused on AIDS-related KS, endemic KS has received relatively little attention. At our 
center, endemic KS appeared to occur at both younger and older ages compared to HIV-
positive KS. Lifelong KSHV infection in sub-Saharan Africa is often acquired in childhood 
through salivary and breast milk transmission, although KSHV may also be acquired in 
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adulthood. Subsequent infection with HIV during adulthood abruptly alters host immune 
function allowing KS development, accounting for high KS burden in the HIV positive 
population between ages 20 and 49 years. In the absence of HIV, precipitating co-factors of 
endemic KS remain unclear and may be associated with volcanic soils, African natural 
products, and genetic predisposition (16-18).  
As antiretroviral therapy (ART) scale-up continues in Malawi, which began in 2004 
with ART coverage now reaching 67% of eligible HIV-positive patients (178), incidence of 
AIDS-associated KS is anticipated to decline. These trends, coupled with demographic shifts 
in sub-Saharan Africa with aging of populations overall, may result in higher proportions of 
KS in older individuals and relatively constant burden among children, regardless of HIV 
status. At our center, many of these patients had severe enough disease to require treatment 
with chemotherapy at a tertiary referral oncology clinic. This may become increasingly 
important, since treatment of older patients with cytotoxic therapy is challenging in resource-
limited settings without appropriate supportive care infrastructure. Novel treatment 
paradigms, including greater application of non-cytotoxic therapies and local treatments for 
limited-stage disease, may therefore be needed. Finally, questions remain as to how endemic 
KS evolves from KSHV infection. Studies in the US and Malawi suggest the presence of at 
least two subtypes of KS on the basis of gene expression profiling (179, 180). Understanding 
precipitating and viral factors in HIV-negative populations may help guide therapy 
development and prevention efforts.  
In conclusion, embedded efforts to better understand endemic KS are needed within 
larger regional initiatives focused on AIDS-related KS. If successful, such efforts have 
potential to guide prevention and treatment strategies which can better address overall KS 
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burden in Malawi and comparable settings, as ART scale-up continues and populations 
continue to age. 
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CHAPTER 3. KAPOSI’S SARCOMA-ASSOCIATED HERPESVIRUS INCREASES 
PD-L1 AND PROINFLAMMATORY CYTOKINE EXPRESSION IN HUMAN 
MONOCYTES2 
OVERVIEW 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is associated with the human 
malignancy Kaposi’s sarcoma and the lymphoproliferative disorders primary effusion 
lymphoma and multicentric Castleman’s disease. KSHV establishes lytic infection of 
monocytes in vivo, which may represent an important cellular reservoir during KS disease 
progression. KS tumors consist of latently infected endothelial cells; however, lytic phase 
gene products are important for KS onset. Early KS lesion progression is driven by 
proinflammatory cytokines supplied by immune cell infiltrates including T cells and 
monocytes. KSHV-infected monocytes may supply the lytic viral products and the 
inflammatory milieu conducive to KS tumor progression.  
To establish successful infection, KSHV extensively modulates the host immune 
system. KSHV antigens activate both innate and adaptive immune responses including 
KSHV-specific T cells, but lifelong infection is still established. Programmed death ligand 1 
(PD-L1) is a prosurvival cell surface protein that suppresses T-cell-mediated killing. PD-L1 
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is variably present on various tumor cells and is a targetable marker for cancer treatment. We 
show that KSHV infection of human monocytes increases PD-L1 expression and 
transcription in a dose-dependent manner. We also saw evidence of lytic gene expression in 
the KSHV-infected monocytes. Intact KSHV is needed for full PD-L1 response in human 
monocytes. KSHV induces a general proinflammatory cytokine milieu including interleukins 
1α, 1β, and 6, which have been implicated in early KS lesion progression. KSHV-mediated 
PD-L1 increase may represent a novel mechanism of KSHV-mediated immune modulation 
to allow for virus survival and eventually malignant progression.  
IMPORTANCE 
KSHV is the etiologic agent of Kaposi’s sarcoma and the lymphoproliferative 
disorders primary effusion lymphoma and multicentric Castleman’s disease. Programmed 
death ligand 1 (PD-L1) is an immunosuppressive cell surface marker that inhibits T cell 
activation. We report that KSHV infection of primary human monocytes upregulates PD-L1 
transcription and protein expression. Analysis of the cytokine and chemokine milieu 
following KSHV infection of monocytes revealed that KSHV induces interleukins 1α, 1β, 
and 6, all of which have been implicated in KS development. Our work has identified another 
potential immune evasion strategy for KSHV and a potential target for immunotherapy of 
KSHV-derived disease. 
INTRODUCTION 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is associated with the endothelium-
derived malignancy Kaposi’s sarcoma (KS) and the B cell lymphoproliferative disorders 
primary effusion lymphoma (PEL), multicentric Castleman’s disease (MCD), as well as 
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cases of germinotropic lymphoproliferative disorder (GLD) (5-7, 181). KS remains the most 
common AIDS-defining malignancy and the leading cause of cancer in sub-Saharan African 
men (3). KSHV-associated disease primarily manifests in immunocompromised patients such 
as solid organ transplant recipients, HIV-positive patients, and the elderly (3). A competent 
immune response is typically sufficient to prevent KSHV-mediated malignancies in the vast 
majority of lifelong KSHV infections. However, the immune system may also aid in early 
KS lesion progression, since a heavy immune cell infiltration and a proinflammatory 
cytokine milieu are present in early KS lesions and aid in lesion progression (21, 22).  
Although reconstitution of the host immune system via highly active antiretroviral therapy 
(HAART) in AIDS-KS or change of immunosuppressive regimens in iatrogenic KS often 
leads to clinical regression of KS (22), an  improper immune response in immune 
reconstitution inflammatory syndrome (IRIS) during HAART-initiated repopulation of CD4+ 
T cells can lead to KS lesion progression (22). Therefore, a proper balance of immune 
response is vital for control of KSHV and prevention of its downstream malignancies.  
Programmed death ligand 1 (PD-L1) (also called B7-H1 and CD274) is an 
immunomodulatory cell surface protein, which interacts with the Programmed death 1 (PD-
1) (CD279) receptor on activated T, B, myeloid, and Natural Killer (NK) cells to induce a 
suppressive costimulatory signal (143-151). T cell receptor (TCR) signaling is blocked by 
PD-1–PD-L1 engagement, which leads to T cell anergy and immune tolerance. PD-L1 is 
constitutively expressed by a wide range of cells and is important in peripheral immune 
tolerance (144, 147, 152-155). PD-L1 is also induced by both type 1 and 2 interferons (154, 
155). Chronic PD-1–PD-L1 interaction results in T cell exhaustion and is utilized by many 
viruses, including HIV, hepatitis C virus (HCV), and HBV, to induce an immune tolerant 
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environment (174-176). A specific T cell response is generated to both KSHV latent and lytic 
antigenic proteins; however, it is apparent that KSHV-infected cells are not effectively 
cleared, since the virus establishes lifelong infection (68, 182). In addition to infections that 
induce increases in the PD-1–PD-L1 axis, cancer cells also upregulate PD-L1 levels (172, 
173, 183-185). Importantly, therapeutic antibodies disrupting the PD-1–PD-L1 interaction 
have shown efficacy in treating PD-L1-overexpressing cancers (126, 128, 129, 186).  
  KSHV is tropic for monocytes both in vivo and in vitro (20, 72, 187-190). Within KS, 
the primary tumor is composed of latently infected spindle cells combined with a small 
subset of lytic cells and inflammatory cell infiltrate.  KS tumor progression is theorized to be 
dependent on proinflammatory cytokines. Cytokine involvement is suggested by the high 
dependency of KS spindle cells in vitro on cytokines for growth, exposure to these required 
cytokines in vitro induces a morphological shift to the classic spindle KS shape in endothelial 
cells, and high levels of proinflammatory cytokines including interleukin 1α (IL-1α), IL-1β, 
and IL-6 are found within the KS tumor microenvironment (21). The contribution of KSHV 
lytic replication to KS tumor development was demonstrated when AIDS patients were 
administered ganciclovir, a lytic phase inhibitor of herpesviruses, and KS incidence was 
significantly reduced (191). The lytic phase of KSHV infection results in the production of 
infectious virus and also induces the expression of all viral genes, which include viral 
homologues of cytokines and chemokines (3). Thus, lytic infection may be both inducing 
inflammation and reseeding tumor cells. Monocytes have been found to support KSHV lytic 
replication and may represent an important reservoir of virus during KS development (20). 
KS is the most common AIDS-defining cancer and coinfection of monocytes with KSHV 
and HIV leads to higher HIV replication (3, 188). Therefore, monocytes may play an 
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important role in KSHV-associated disease. Previous studies have found that KSHV-positive 
PEL and GLD tumor cells are highly PD-L1 positive (192, 193) and that KS patient NK cells 
have increased PD-1 levels (194). Other infection events such as chronic infection of HIV 
and HBV also result in increased PD-L1 levels on CD14+ monocytes, which may establish 
an immune tolerant environment to allow for long-term infection (176, 195). A similar 
situation may be occurring with KSHV infection. 
KSHV modulates the host immune system to successfully establish lifelong infection. 
During both the lytic and latent phases of KSHV’s life cycle, immunomodulatory genes are 
expressed. KSHV is able to disrupt a wide range of immune responses from innate immune 
sensing molecules, including Toll-like receptors, Nod-like receptors, and retinoic acid-
inducible gene I product (RIG-I)-like receptors, to adaptive immune mechanisms, such as 
downregulation of major histocompatibility complex I (MHC-I) antigen presentation and 
expression of immunosuppressive viral cell surface homologues (84). Increased expression 
of PD-L1 may represent a novel pathway of immune suppression facilitated by KSHV.  
We report that de novo infection of primary monocytes with KSHV induces increased 
PD-L1 levels through increased PD-L1 gene transcription. We also found evidence of lytic 
gene expression in the KSHV-infected monocytes. UV-inactivated KSHV failed to induce 
similar PD-L1 increases, suggesting that infection with KSHV is driving PD-L1 increase. 
Infection with increasing doses of KSHV correlate with increasing PD-L1 surface expression 
and transcription. KSHV-infected monocytes produce a general proinflammatory response 
similar to the KS tumor microenvironment cytokines with enrichment of IL-1α, IL-1β, and 
IL-6 compared to uninfected control cells. Overall, these data suggest that KSHV infection of 
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monocytes may promote an immune tolerant environment and a cytokine milieu potentially 
allowing for both viral evasion and oncogenic progression. 
 RESULTS  
KSHV infection upregulates PD-L1 surface expression on monocytes. 
As KSHV has evolved multiple strategies for evasion of the immune response, we 
hypothesized that KSHV may modulate the PD-1–PD-L1 pathway. Monocytes are 
permissive for KSHV infection (187) and express PD-L1 (146). Therefore, we investigated 
whether KSHV infection of monocytes could alter expression of PD-L1. Primary human 
monocytes were isolated using negative selection from human peripheral blood mononuclear 
cells (PBMCs). The monocytes were then infected with intact KSHV, ultraviolet (UV) light-
inactivated KSHV, or PBS (mock infected). Cells were harvested at 24, 48, or 72 h 
postinfection (hpi), and PD-L1 levels were measured via cell staining and flow cytometry. 
This analysis was performed with 14 different human donors at multiple time points after 
KSHV infection. CD14-positive monocytes show increased PD-L1 surface expression 
following KSHV infection at 24 hpi through 72 hpi (Figure 3.1A). Intact KSHV is necessary 
for the increase in PD-L1 following infection (Figure 3.1B). Whole-cell lysates harvested at 
36 hpi show increased PD-L1 protein expression following KSHV infection compared to 
mock-infected cells (Figure 3.1C). We consistently observed an increase in PD-L1 protein 
expression in CD14-positive cells compared to mock-infected cells from all donors (Table 
3.1). The fold increase varies from 5.8-fold to more than 106-fold depending on the 
individual donor. These data suggest that infection of monocytes with KSHV results in a 




Figure 3.1. PD-L1 protein expression following KSHV infection. Primary human 
monocytes were isolated from buffy coats, and 5 × 106 monocytes per well were infected 
with KSHV (2 × 109 genomes/well). The cells were harvested at 24, 48, or 72 h postinfection 
and stained for CD14 and PD-L1, and expression of these markers was measured by flow 
cytometry. Cells were gated on forward scatter, side scatter, and CD14+. Histograms indicate 
the gate of PD-L1-positive cells with the gray-shaded histogram showing the percentages of 
mock-infected cells and the histogram outlined by the thick black line showing the 
percentages of KSHV-infected cells. (A) Representative histogram of the general trend from 
14 independent donors. (B) Percent CD14+ cells expressing PD-L1 at 24 to 48 h after 
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exposure to KSHV versus mock treatment or exposure to UV-treated KSHV (UV) for 48 h. 
The values between the KSHV-infected and mock-infected cells or the KSHV-infected and 
UV-inactivated KSHV-infected cells were significantly different (P ≤ 0.00001) by ANOVA 
posthoc comparison adjusted for multiple comparison by Tukey’s honestly significant 
difference test (HSD). (C) PD-L1 protein expression by immunoblotting at 36 h after KSHV 
















Table 3.1. Percentages of cells expressing PD-L1 following KSHV primary infection at 
24, 48, and 72 h postinfection. 
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As PD-L1 expression on the surfaces of monocytes increased in KSHV-infected cells 
compared to mock-infected cells, we hypothesized that this may be due to an increase in PD-
L1 transcription. RNA was harvested from mock-infected and KSHV-infected cells at 24, 48, 
and 72 h, reverse transcribed, and subjected to real-time PCR (RT-PCR) (C) to assess PD-L1 
transcript levels. All PD-L1 transcript levels were normalized to β-actin message. PD-L1 
transcription peaks at 24 h postinfection and then tapers off at 48 and 72 h postinfection 
(Figure 3.2A). The general trend was observed for 14 donors with various infectious doses 
and time points analyzed; 24 hpi (n = 14), 48 hpi (n = 9), and 72 hpi (n = 8). These data 
suggest that infection with KSHV increases PD-L1 transcription at early time points and that 
while the protein level (Figure 3.1C) remains high, message levels decrease over time. 
To ensure that the increase in PD-L1 message and level of expression is due to 
primary KSHV infection, the level of KSHV RNA present inside the infected monocytes was 
assessed. RNA was extracted from monocytes at 48 h after infection with either intact KSHV 
or UV-inactivated KSHV. The levels of viral interleukin-6 (vIL-6) were quantified via real-
time PCR for message levels at 48 h postinfection (196). KSHV vIL-6 at 48 hpi showed 
increasing levels correlated with increasing dosages of intact KSHV (Figure 3.2B) (24 and 
72 hpi data not shown). KSHV transcripts were virtually undetected in mock-infected or UV-







Figure 3.2. Levels of PD-L1 transcripts increase following KSHV infection. Human 
monocytes (5 × 106 monocytes/well) were infected with KSHV (1 × 109 genomes/well) (A 
and B) or UV-inactivated KSHV (B) for 24, 48, or 72 h. Total KSHV genomes were 
calculated prior to infection for panel B, and different amounts of KSHV genomes per well 
(5.6 × 107, 2.5 × 108, 5.6 × 108, and 1.7 × 109) were used. UV-inactivated KSHV genomes 
used were 1.7 × 109 per well. At each time point, a mock-infected control was also harvested. 
After harvest, RNA was isolated from cells and reverse transcribed, and cDNA levels were 
measured through quantitative real-time PCR to assess either PD-L1 (A) or KSHV-encoded 
viral interleukin-6 (vIL-6) (B) message levels. RNA levels were normalized to β-actin and 
are represented as fold increase over mock-infected values at each time point. The data are 
representative plots of single experiments but represent the general trend of 11 donors for 
PD-L1 (24 hpi) transcript levels and 5 donors for vIL-6 (48 hpi) transcript levels. Error bars 
represent standard deviations of the fold change values for three technical replicates. 
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KSHV displays lytic infection at 48 h postinfection in monocytes. 
Similar to other herpesviruses, KSHV infection displays either a latent or lytic life 
cycle (48). We infected primary human monocytes with KSHV, and cells were harvested at 
48 hpi. We determined the levels of various lytic KSHV transcripts via RT-PCR including 
the following: vIL-6, open reading frame 39 (ORF39), ORF57, ORF59, K8.1, viral interferon 
regulatory factor 1 (vIRF1) and replication and transcription activator (RTA) (48, 81, 197) 
(Fig. 3.3A). Further, we determined the protein level of the lytic KSHV ORF45 protein via 
western immunoblotting (198) (Fig. 3.3B). The presence of both lytic transcripts and protein 










Figure 3.3. KSHV establishes lytic infection of human monocytes at 48 h postinfection. 
Human monocytes (5 × 106 monocytes/well) were infected with KSHV (8.7 × 107 
genomes/well) for 48 h. At each time point, a mock-infected control was also harvested (A 
and B). (A) After harvest, RNA was isolated from cells and reverse transcribed, and cDNA 
levels were measured using quantitative real-time PCR to assess KSHV-encoded viral 
interleukin-6 (vIL-6), open reading frame 39 (ORF39), ORF57, ORF59, K8.1, viral 
interferon regulatory factor 1 (vIRF1), and replication and transcription activator (RTA) 
message levels as normalized to β-actin and represented as fold increase over mock-infected 
values. Error bars represent the standard deviations of fold change values for three technical 
replicates. (B) Immunoblot of KSHV viral protein ORF45 at 48 h postinfection. The data are 
representative plots of single experiments but represent the general trend of at least two (A) 




PD-L1 response is dependent on infection with intact KSHV. 
We investigated the ability of UV-inactivated KSHV virions to increase PD-L1 levels 
at 48 h postinfection (Figure 3.4A). PD-L1 surface protein levels were increased by intact 
KSHV virions; however, UV-inactivated KSHV did not induce an increase in PD-L1 similar 
to the level induced by intact KSHV (Fig 3.4A). Infection with UV-inactivated KSHV 












Figure 3.4. Infection with intact KSHV results in increased PD-L1 expression. Primary 
human monocytes (5 × 106 monocytes/well) were infected with either intact or UV-
inactivated KSHV (9.5 × 108 genomes/well) and harvested at 48  h postinfection (A and B). 
(A) Cells were gated on forward scatter, side scatter, and CD14+. Histograms indicate the 
percentages of PD-L1-positive cells with the percentages for mock-infected cells, UV-
inactivated KSHV-infected cells, and high-dose KSHV-infected cells. The results shown in 
panel A are representative of the results from four independent human donors. (B) RNA was 
isolated from cells and reverse transcribed, and cDNA levels were measured through 
quantitative real-time PCR to assess PD-L1 message levels. RNA levels were normalized to 
β-actin and represented as fold increase over mock-infected monocytes. Error bars represent 
standard deviations of fold change values for three technical replicates. The data are 





KSHV-mediated increase in PD-L1 expression is dose dependent. 
We next investigated whether there was a correlation between the dose of virus used 
for infection and the levels of PD-L1 and cytokine production. Monocytes isolated from the 
same donor were infected with a low dose of KSHV (3 x 108 genomes/well) and a high dose 
of KSHV (2.1 x 109 genomes/well). At both 24 and 72 h postinfection, the cells that were 
infected with the higher dose of virus expressed higher levels of PD-L1 on the cell surface 
than the cells infected with the low dose of virus (Figure 3.5A). This effect was observed 
with multiple donors (Figure 3.5B). To better understand the general monocytic PD-L1 
response to herpesviruses, we also infected monocytes with herpes simplex virus 1 (HSV-1) 
at multiplicities of infection (MOIs) of 0.02 and 0.2. The PD-L1 response to HSV-1 showed 
a similar dose-dependent increase to increasing HSV-1 doses (Figure 3.5C). Moreover, an 
increase in PD-L1 protein was accompanied by an increase in PD-L1 message in infected 
cells compared to mock-infected cells (Figure 3.5D). Again, the message increase was 
variable between donors, but the general trend remained the same over 7 donors. These data 
suggest that increased doses of KSHV and HSV-1 correlate with the increase in PD-L1 
transcription and protein production. 
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Figure 3.5. Increase in PD-L1 expression is dose dependent. Primary human monocytes (5 
× 106 monocytes/well) were infected with a low dose of KSHV (3 × 108 genomes/well) or a 
high dose of KSHV (2.1 × 109 genomes/well) or mock infected and harvested at 24 and 72 h 
postinfection. (A and B) Cells were stained for CD14 and PD-L1, and expression of these 
markers was measured by flow cytometry. Cells were gated on forward scatter, side scatter, 
and CD14+. Histograms indicate the gate of PD-L1-positive cells with percentages for mock-
infected cells, low dose of KSHV-infected cells, and high dose of KSHV-infected cells 
shown. Panels A and B show representative data from donors from seven independent 
experiments. (C) Monocytes from a donor were infected with low-dose HSV-1 (MOI of 
0.02) and high-dose HSV-1 (MOI of 0.2). (D) RNA was isolated from mock- and KSHV-
infected cells and reverse transcribed, and cDNA levels were measured through quantitative 
real-time PCR to assess PD-L1 message levels. RNA levels were normalized to β-actin and 
represented as fold increase over the values for mock-infected monocytes. Error bars 
represent standard deviations of the fold changes for three technical replicates. The data are 
representative of the general trend of seven independent donor experiments. 
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Multiple cytokines and chemokines are induced in monocytes following KSHV infection. 
PD-L1 expression can be driven by cytokine signaling pathways (199). Further, 
cytokines and chemokines play a role in KS tumor progression, particularly early in lesion 
development (21, 22). Therefore, we determined the production of a panel of cytokines and 
chemokines by KSHV-infected monocytes at 24, 48, and 72 h postinfection. The average 
cytokine levels in 14 donors at 24 h postinfection are shown in Table 3.2. At first glance, the 
levels of nearly all of the 35 analytes tested were increased in response to KSHV infection in 
monocytes compared to mock-infected monocytes (Table 3.2). In time course experiments, 
cytokines that were increased at 24 h postinfection exhibited higher levels at 48 and 72 h 
(data not shown). Cytokines that were increased at lower levels of KSHV infectious dose 
exhibited higher levels at higher levels of infectious dose (data not shown). Yet, there was 
also considerable random variation among donors, as would be expected for experiments 
with primary cells. To account for the random variation and experimental variation, we used 
multivariate analysis of variance (ANOVA). To account for multiple comparisons, we used 
Dunnett’s posthoc test on fold enrichment scores calculated on matched infected and mock-
infected cells from the same donor. Furthermore, the data were Z standardized to allow 
comparison across different ranges of responses. Figure 3.6A shows the relative response on 
the horizontal axis compared to Eotaxin, which did not change in any of the experiments; 
epidermal growth factor (EGF), alpha interferon (IFN-α), IL-1α, IL-1β, IL-6, IL-15, IL-17F, 
and IL-2 receptor (IL-2R) and the chemokines IP-10 (interferon-inducible protein of 10 
kDa), MIP-1α (macrophage inflammatory protein 1α), MIP-1β, RANTES (regulated on 
activation, normal T cell expressed and secreted), and alpha tumor necrosis factor (TNF-α) 
changed significantly. Raw concentrations for significantly changed cytokines are shown in 
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Figure 3.6B, for each of the donors.  The changes in IL2R and IL-17F were minimal but 
consistent across donors and conditions. IL-10 only increased in about half of all donors. 
Whether IL-6, MIP-1α, MIP-β, or RANTES Luminex beads exhibit cross-reactivity to the 
respective viral homologues is not known. 
Interestingly, levels of nearly all of the 35 analytes tested were increased in response 
to KSHV infection in monocytes compared to mock-infected cells (Table 3.2). Monocyte 
chemotactic protein 1 (MCP-1) was included in the assay plate; however, regardless of 
conditions, readings regularly exceeded upper threshold and were excluded from analysis.  
Finally, KSHV increases IP-10 at each time point (Table 3.2) which correlates with our 
previous report that KSHV can activate Toll-like receptor 3 (TLR3), resulting in the 




Table 3.2. Average increase in cytokines and chemokines 24 h after KSHV infection. 
FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, 
granulocyte-macrophage colony-stimulating factor; EGF, epidermal growth factor; HGF, 
hepatocyte growth factor; VEGF, vascular endothelial growth factor; MIG, monokine 








Figure 3.6. Cytokine response following KSHV infection. Supernatants from KSHV-
infected and mock-infected monocytes were harvested at 24, 48, and 72 h postinfection. 
Supernatants were precleared and then subjected to the human cytokine magnetic 35-plex 
panel. The average raw values (in picograms per milliliter) of 35 analytes were measured. 
(A) Multivariate analysis after individual enrichment compared to matched mock value for 
the same donor was calculated, and data were Z standardized. The relative response on the 
horizontal axis compared to eotaxins is shown, which did not change in any of the 
experiments after adjustment for multiple comparisons by Dunnett’s posthoc test. The 95% 
confidence intervals (95% CI) of the response variables are also shown by the bars. 95% CIs 
that do not include zero are considered significant at P ≤ 0.05. (B) A box-and-whisker plot of 
cytokine levels in picograms per milliliter on the vertical axis in the supernatant of KSHV-
infected and mock-infected monocytes for a group of cytokines that significantly and 
consistently increased upon KSHV infection. Note that the vertical axis is on a log10 scale. 
The horizontal axis indicates the different donors. The donors are ordered by mean 
enrichment to KSHV infection and not by unique identifier. The median values (horizontal 
bars), first and third quartile boundaries (boxes), and the 1.5× interquartile ranges (vertical 
bars) are shown for the cytokines measured shown at the top of each subpanel. Blue indicates 
mock-infected samples, and red indicates KSHV-infected samples. Note that some donors 
were exposed to different concentrations of virus, and measurements were taken at different 
time points (24, 48, and 72 h) after infections. These are aggregated here and explain some of 
the variation. The other 23 analytes in the human cytokine magnetic 35-plex panel did not 
show consistent changes upon KSHV infection. MCP-1 was excluded from the analysis, as 
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the readings were consistently above the upper limit of the assay. A total of 14 independent 
donors were used. 
DISCUSSION 
In this report, we show that KSHV infection of human primary monocytes results in 
an increase in PD-L1 expression. This increase was at the transcriptional level, and although 
transcript levels decreased over time, protein levels remain increased at least until 72 h after 
primary infection with KSHV. We show that at 48 h postinfection of monocytes, KSHV 
expresses multiple lytic transcripts and the lytic protein ORF45, suggesting establishment of 
an overall lytic phase of infection. Cells that were exposed to increasing amounts of virus 
exhibited increased KSHV vIL-6 transcription as well as increased PD-L1 transcription and 
protein expression. In addition to an increase in PD-L1 expression, infected cells also 
increased production of a variety of generally proinflammatory cytokines and chemokines. 
Together these data suggest that KSHV induces an immune response in cells and one of the 
potential mechanisms that KSHV may utilize to decrease immune responses is through 
upregulation of the immunomodulatory protein PD-L1. 
KSHV-mediated expression of PD-L1 may be an additional mechanism among many 
already identified for KSHV evasion of host immune responses. It is critical that KSHV 
avoid detection in order to maintain lifelong infection within the host. To this end, 
mechanisms for blockade of many major immunological pathways have already been 
identified including the host complement system, type I Interferons, Toll-like Receptors, 
Nod-like receptors, and cytosolic DNA sensors (200). For many of these pathways, KSHV 
encodes homologues of cellular proteins which inhibit the pathway such as vIL-6, CD200, 
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and vIRFs. KSHV also expresses some mechanisms to evade adaptive immune responses, 
such as downregulation of MHC-I (200).  
The role of PD-1–PD-L1 in acute infection is not as widely studied as in the chronic 
infection setting (201). Our data examine PD-L1 modulation during acute infection. Due to 
the fact KSHV establishes lifelong infection in the host, this means that primary infection of 
naïve cells takes place sporadically throughout the life of the host following bouts of viral 
reactivation from latency (3). Spontaneous production of viral progeny likely results in 
periodic infection of naïve cells such as monocytes. Although our data show that PD-L1 
levels increase in acute KSHV infection, it is possible that repeated primary infection may 
result in chronic PD-L1 upregulation in monocytes. Our data also reveal a potential 
mechanism of host evasion utilized by KSHV to establish infection. A previous report has 
shown that KS patient NK cells have increased PD-1 surface expression and show an 
exhausted phenotype upon stimulation in vitro (194). Further, inflammatory infiltrates within 
the KS tumor microenvironment were shown to express PD-L1 (194). As monocytes are a 
common infiltrate of KS tumors, our data suggest that KSHV primary infection of monocytes 
may be in part contributing to increases in PD-L1 expression and downstream PD-1–PD-L1- 
induced NK cell exhaustion. Further, KS tumor progression is highly dependent on 
inflammatory cytokines in the tumor microenvironment. We report that KSHV induces an 
overall proinflammatory cytokine milieu including IL-1α, IL-1β, and IL-6, which have all 
been reported to be important for KSHV-derived malignancies (21, 22). Finally, previous 
reports have also shown that PEL and GLD tumor cells can display increased PD-L1 
expression (192, 193).  
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As PD-L1 and PD1 are overexpressed in a subset of cancers and therapies to block 
these pathways have helped to reduce tumor burdens, expression of PD-L1 in KSHV-
infected cells could be of great interest to reduce KSHV persistence and associated 
malignancies. Further investigation of KSHV-modulated PD-L1 expression may reveal 
individual viral genes responsible for upregulating PD-L1 and potential mechanisms for 
targeted treatment of KSHV-associated cancers. 
MATERIALS AND METHODS 
Monocyte Isolation, Virus generation, and Infection 
Human monocytes were isolated from buffy coats (Gulf Coast Regional Blood 
Center) using the Monocyte Isolation Kit II (Miltenyi Biotec) according to the 
manufacturer’s instructions. The CD14-positive monocytes were assayed for purity, and in 
all experiments, only a ≥85% pure monocyte population was used.  The resulting monocytes 
were plated into six-well dishes at 5 x106 cells/well in RPMI medium.  
Kaposi’s sarcoma-associated herpesvirus (KSHV) was isolated from iSLK.219 cells 
harboring latent recombinant KSHV.219 (rKSHV.219) (202). iSLK.219 cells were 
maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) (Cellgro), 1% penicillin and streptomycin (Pen-Strep), G418 (250 
μg/ml), hygromycin (400 μg/ml), and puromycin (10 μg/ml) (202). To produce infectious 
virions, the medium was changed to DMEM containing 1% Pen-Strep, 10% FBS, and 3 
μg/ml of doxycycline, and 1 mM Sodium Butyrate (202). After 72 h, supernatant was 
harvested, and cell debris was pelleted and filtered through a sterile 0.45-μm filter. Virus was 
concentrated as previously described (74). UV inactivation of KSHV was performed as 
previously described (72). 
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Human monocytes were centrifuged with a range of KSHV doses from 4.2 x 107 to 
7.8 x 109  genomes/well and 10 μg/mL polybrene in serum-free RPMI medium at 2,500 rpm 
for 90 min at 30°C as previously described (72). Mock-infected cells were treated with an 
equivalent volume of phosphate-buffered saline (PBS), the buffer utilized to concentrate 
KSHV. Immediately following centrifugation, fetal bovine serum was added to the medium 
at a final concentration of 20%. The cells and medium supernatants were harvested at the 
times indicated. 
Flow Cytometry 
Cells were stained with CD14 (61D3; eBioscience) and PD-L1 (29E.2A3; Biolegend) 
prior to analysis on a MACSQuant VYB cytometer (Miltenyi Biotec) and FlowJo software 
(Tree Star). Programmed death ligand 1 (PD-L1) levels were ascertained after gating on 
CD14. 
Immunoblots 
Cells were harvested, washed once with PBS, and then lysed. Lysis was mediated 
through two separate methods depending on cell number harvested. For samples less than or 
equal to 5 x 106 monocytes, cells were resuspended in 40 microliters of a solution of 50 mL 
NP-40 buffer (0.1% NP-40, 150 mM NaCl, 50 mM Tris-HCL [pH 8.0] containing a 
proteinase inhibitor tablet [Roche], 30 mM β-glycerophosphate, 50 mM NaF, and 1 mM 
Na3VO4) and subsequently frozen and thawed once to complete lysis. For samples more than 
5 x 106 monocytes, cells were resuspended in 2X Laemmli Sample Buffer and 
simultaneously boiled and vortexed at 1,200 rpm in a ThermoMixer (Eppendorf) until the 
pellet was no longer visible (10 to 20 min). Equal amounts of protein were loaded per lane, 
and resolved by SDS-PAGE, and then transferred to a nitrocellulose membrane. The 
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antibodies used were PD-L1 (E1L3N; Cell Signaling Technology), ORF45 (2D4A5; Thermo 
Fisher), and Actin (C-11; Santa Cruz).   
Nucleic acid Isolation and real-time PCR 
RNA was isolated using RNeasy Micro kit (Qiagen) and reverse transcribed with 
SuperScript III reverse transcriptase (Invitrogen) and oligo(dT) (Invitrogen). Real-time PCR 
was performed on a QuantStudio 6 Flex (Applied Biosystems) with PowerUp SYBR green 
PCR master mix (Applied Biosystems). The PCR was carried out with 1 cycle of 50°C for 2 
min and 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. All 
fold activations were normalized to β-actin. The primer sequences used for β-actin and PD-
L1 were as follows:  for β-actin, forward, 5’-TCATGAAGTGTGACGTGGACATC, and 
reverse, 5’-CAGGAGGAGCAATGATCTTGATCT (203); for PDL1, forward, 5’ –
GGTGCCGACTACAAGCGAAT, and reverse, 5’-AGCCCTCAGCCTGACATGTC (204). 
Proprietary PD-L1 primers (SA Biosciences) were also used and showed threshold cycle 
(CT) values similar to those of the aforementioned primers. The forward and reverse primers 
for cytokines, chemokines, and other targets follow: for viral IL-6 (vIL-6), forward, 5’-
CGGTTCACTGCTGGTATCT, and reverse, 5’ –CAGTATCGTTGATGGCTGGT (196); for 
open reading frame 39 (ORF39), forward, 5’ -GGTTTCCCCTGCTACTTCAA and reverse, 
5’ –CATGCTTGGCCCGATATAC; for ORF57, forward, 5’ –
TGGACATTATGAAGGGCATCCTA, and reverse, 5’ –CGGGTTCGGACAATTGCT; for 
ORF59, forward, 5’ –TTGGCACTCCAACGAAATATTAGAA, and reverse, 5’-
CGGAACCTTTTGCGAAGA;  K8.1, forward, 5’ -AAAGCGTCCAGGCCACCACAGA 
and reverse, 5’ –GGCAGAAAATGGCACACGGTTAC; for replication and transcription 
activator (RTA), forward, 5’ –TGTAATGTCAGCGTCCACTC, and reverse, 5’ –
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ATTGCTGGGCCACTATAACC; for viral interferon regulatory factor 1 (vIRF1), forward, 
5’-CGTGTCCTTTGGTGAAACTG, and reverse, 5’-TCGGCATTATTTCGAGTACG (81). 
Cytokine and Chemokine Determination 
Supernatants were precleared and tested with a human cytokine magnetic 35-plex 
panel (Life Technologies) as per the manufacturer’s instructions and analyzed with a 
MAGPIX instrument (Luminex). 
Statistical analysis 
All calculations were conducted using the R software package version 3.3.3 “Another 
Canoe" (released 6 March 2017) with the specific statistical tests as indicated. Code is 










CHAPTER 4. SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
GENERAL SUMMARY 
My dissertation research has focused on the interaction of KSHV with the host 
immune system, performed under the guidance of Dr. Blossom Damania. In particular, 
focusing on the clinical impact of KSHV mediated disease (1) and the modulation of PD-L1 
by KSHV (2). My work has highlighted the significant burden currently posed by KS in the 
absence of obvert immune suppression, thereby guiding future research efforts within a 
severely resource-restricted setting. In addition, my studies have highlighted the involvement 
of an immunosuppressive surface marker in KSHV infection, which may prove to be not 
only valuable for understanding the viral lifecycle but could be a chemotherapeutic target.  
Although two separate projects comprise my dissertation research one central theme 
emerges: the interaction of KSHV with the host immune system. In Chapter One, a current 
view of KSHV clinical impact, KSHV virology, immune checkpoint therapy, and PD-L1 
regulation is discussed. Chapter Two shows that current burden of KS is primarily in HIV-
infected individuals in Malawi yet still shows a significant number in HIV naïve patients 
(9%). As HIV control continues to improve and Malawians enjoy predicted improvements in 
life expectancy, the endemic KS burden is expected to grow. We know surprisingly little 
about endemic KS, posing a problem for future prevention and treatment. In Chapter Three, I 




upregulation is dose dependent and similar to HSV-1 infection. KSHV infection results in 
proinflammatory cytokine induction, of which, IL-1α, IL-1β, and IL-6 are highly upregulated 
and have been previously found within KS tumor tissue. Thus, my studies have spanned 
clinical observations to basic innate signaling mechanisms, yet all revolve around the 
immune system’s ability to control KSHV. This chapter distills these two projects, providing 
future directions to allow for better understanding of KSHV virology and ways in which to 
combat its pathology. 
KAPOSI’S SARCOMA IN MALAWI: A CONTINUED PROBLEM FOR HIV-
POSITIVE AND HIV-NEGATIVE INDIVIDUALS 
KS was first described in 1872 and endemic regions had been noted for years prior to 
HIV emergence. Initially KS was divided into KS and African KS, as the African variant 
seemed to affect a wider range of patient populations. African KS presented in young and 
old, male and female, whereas KS in the Mediterranean was isolated to geriatric males (19). 
The spread of HIV and the realization that KS presented similarly to a sexual infectious 
disease in western countries, lead to the discovery of KSHV in 1994 (5). Although we have 
made an astounding amount of progress in the last 24 years, surprisingly little is understood 
about African KS or what is now termed endemic KS. 
 I set out to better understand the current burden of endemic and AIDS-KS in Malawi, 
a setting of high prevalence of both HIV (10% of adults) and KSHV (>40% of adults) (50, 
178). In a report published in AIDS (1), I found that AIDS-KS is indeed the primary 
constituent of current burden yet endemic KS still makes up 9% of KS cases. KS is the 
leading cause of cancer in Malawi and endemic KS makes up a significant proportion of the 
current burden, yet we know surprisingly little about this KS substype. Multiple theories 
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have been put forward for co-factors in endemic KS including associations with volcanic 
soils, African natural products, and genetic predisposition (16-18). In addition to host factors, 
viral variants have been identified (179, 180). On presentation of KS, if the patient has an 
observable immune disruptor such as HIV or immunosuppressant drugs, control or removal 
of the disruptor can result in KS regression.  Thus, a thorough understanding of risk or 
precipitating factors of endemic KS is necessary for prevention and for informing treatment 
regiments. Long term epidemiologic tracking of at risk populations would help to identify the 
most important factors for developing endemic KS. Sequencing technology would now allow 
in-depth knowledge of human and viral variance from relatively small sample procurements. 
Further, as technology continues to spread into villages of Malawi, identification of personal 
habits, diet, and herbal use could be garnered easier than ever before. Finally, such efforts 
could better enhance our understanding of KSHV virology and course, as primary infection is 
tricky to study given the paucity of symptoms. My quantification of the current burden of 
endemic KS could be a small step in a much greater understanding of this cancer subtype.  
KAPOSI’S SARCOMA-ASSOCIATED HERPESVIRUS INCREASES PD-L1 AND 
PROINFLAMMATORY CYTOKINE EXPRESSION IN HUMAN MONOCYTES 
The immune system plays a vital role in clearing many tumor types. Virus-infected 
tumor cells are prime targets of immune elimination if the immune system can function 
properly. One avenue of immune disruption is immune checkpoint modulation. These 
molecules are cell surface markers which act to suppress T cell responses (discussed in 
Chapter One). PD-L1 has garnered much attention, as it is an immune checkpoint molecule 
upregulated by multiple tumor types. Further, current therapies blocking PD-L1 are showing 
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efficacy (discussed in Chapter One). KSHV is recognized by the immune system, generates 
antigen specific T cells, and yet is able to establish lifelong infection.  
 In my mBio publication (2), I discovered that KSHV infection in monocytes induced 
both PD-L1 and a proinflammatory milieu. Previous reports had seen some activation in the 
PD-1:PD-L1 axis in KSHV mediated disease, but my report was the first to show that KSHV 
infection resulted in PD-L1 upregulation (192-194). Although KSHV malignancies are not 
derived from monocytes, my findings highlight a potentially interesting role for them in 
KSHV pathology (Fig 4.1). KS tumor tissue is infiltrated by immune cells which include 
monocytes (20). It is likely that naïve monocytes are chronically introduced within the KS 
tumor microenvironment, which also harbors KSHV. Therefore, repeated primary infection 
events likely happen within these recruited, naïve monocytes, thereby generating at least a 
local PD-L1 response. Currently, we do not know if PD-L1 expression on monocytes 
protects from T cell mediated cytotoxicity, as would be expected (Fig 4.1A). I found that 
monocytes are lytically infected with KSHV at 48 hours post infection. KSHV lytic products 
help drive oncogenesis yet the majority of KSHV infected tumor cells are latently infected. 
Thus, KSHV may be establishing a lytic reservoir within monocytes, and this reservoir could 
help drive tumor progression through spindle cell reinfection and viral lytic products (Fig 
4.1B) (205). If protection is garnered by PD-L1 expression, KSHV may be utilizing PD-L1 
to protect a viral lytic reservoir in monocytes (Fig 4.1B). If chronic influx and infection of 
naïve monocyes results in chronic increases in local PD-L1 within the tumor 
microenvironment it may suppress T cell mediated killing of KS tumor cells (Fig 4.1C). If 
the proposed model is correct, PD-1:PD-L1 stands to impact multiple facets of KSHV 
lifecycle and pathogenesis (Fig 4.1D). PD-L1 blockade would be expected to alleviate 
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inhibition of T cell mediated cytotoxicity (Fig 4.1A), thereby potentially reducing a lytic 
KSHV reservoir (Fig 4.1B). Further, previous work has shown that proinflammatory 
cytokines can drive KS progression (21). My cytokine analysis details many of the 
implicated cytokines and finds IL-1α, IL-1β, and IL-6 upregulated, which have all been 
reported to be important for KSHV derived malignancies (21, 22).  Thus, KSHV may be 
driving oncogenesis through monocyte cytokine production and PD-1:PD-L1 blockade may 
reduce KSHV induction of these cytokines. More importantly, if PD-L1 is chronic within the 
tumor microenvironment (Fig 4.1C) then PD-1:PD-L1 blockade may allow T cell mediated 
tumor cytotoxicity (Fig 4.1E). To begin solidifying our model, future work should aim at T 
cell challenge of KSHV infected monocytes to determine if PD-L1 is indeed protecting 
KSHV infection (Fig 4.1A, B). Previous work has shown that KS patient NK cells have 
increased PD-1 and show an exhausted phenotype when challenged ex vivo, suggestive of 
chronic PD-1 ligation (194). Future work should examine if KS patient T cells are also 
anergic to ex vivo challenge (Fig 4.1C). Finally, the model suggests that PD-1:PD-L1 
blockade may be efficacious in KS patients (Fig 4.1 D, E), as such a clinical trial could give 
the most relevant evidence for the current model. Even in the absence of increased tumor 
toxicity (Fig 4.1E), KSHV upregulation of PD-L1 in monocytes may be protecting a lytic 
reservoir important for the viral lifecycle (Fig 4.1B). My discovery of PD-L1 induction by 
KSHV has highlighted another potential immune evasion strategy for KSHV, suggested a 
more extensive role of monocytes in KS (Fig 4.1), and identified a novel, targetable marker 
for therapeutics during KSHV infection (Fig 4.1D). In addition to monocytes, KSHV infects 
a wide range of cells and KSHV associated malignancies are derived from endothelial cells 
and B cells. KSHV may be also drive PD-L1 in these cell types, thereby directly protecting 
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pre-malignant or malignant cells from T cell clearance. Future work should ascertain the 
cellular range of KSHV induction of PD-L1. In addition, PD-L1 is not the only immune 
checkpoint molecule, as such, KSHV may upregulate others as well. Future work should 









Figure 4.1. Possible Role for PD-L1 in KSHV Lifecycle and Pathogenesis. We have 
shown KSHV infection of monocytes results in PD-L1 upregulation. We propose that PD-L1 
on KSHV infected monocytes may inhibit T cell mediated cytotoxicity via PD-1 ligation (A). 
KSHV establishes lytic infection within monocytes, thus, PD-L1 may be protecting a viral 
lytic reservoir which may further spread the KSHV virus and re-infect KS tumor spindle cells 
(B). Chronic PD-1:PD-L1 ligation results in T cell exhaustion, therefore if KSHV stimulated 
PD-L1 is upregulated long term it may protect KS tumor cells (C). PD-1:PD-L1 blockade (D) 
may allow T cell clearance of KSHV infected monocytes thereby reducing the lytic reservoir 
and alleviating T cell exhaustion resulting in increased tumor cytotoxicity (B, E). Cells, 
receptors, and virus not drawn to scale. 
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My discovery of PD-L1 induction is highly exciting for the field but leaves much 
room for investigation. It will be important to explore the mechanism of PD-L1 induction by 
KSHV (Fig 4.2). KSHV infection of monocytes results in increased PD-L1 transcription and 
expression (2). Further, KSHV infection of monocytes results in a proinflammatory milieu 
(2). KSHV may be driving PD-L1 expression via direct (Fig 4.2A) or indirect (Fig 4.2B) 
mechanisms. As KSHV enters monocytes it is sensed by pathogen recognition receptors 
(PRRs) (discussed in Chapter One). PD-L1 is inducible by a wide variety of stimuli including 
Toll-like receptor (TLR) stimulation and by both type 1 and 2 interferons (154, 155, 164, 
165). The promoter region of PD-L1 contains elements responsive to nuclear factor-kappa B 
(NF-κB) and interferon regulatory factor 1 (IRF-1) (156, 170). KSHV infection of monocytes 
stimulates TLR3 activation, IRF-1 upregulation, PD-L1 transcription, and type I interferon 
response (2, 72). Immune sensing of KSHV primary infection may be stimulating an innate 
immune cascade resulting in PD-L1 expression (Fig 4.2A). Future work could determine if 
TLR3 activation is necessary and sufficient for PD-L1 stimulation. Next, PD-L1 may be 
driven by KSHV encoded ORF signaling (Fig 4.2A). Future work could screen PD-L1 









Figure 4.2. KSHV Induction of PD-L1 in monocytes: Potential for Direct and Indirect  
Mechanisms. We have shown KSHV infection stimulates PD-L1 transcription and 
expression in human monocytes, however, the mechanism remains unclear. (A) KSHV 
infection may stimulate pathogen recognition receptors (PRRs) and/or result in viral open 
reading frame (ORF) expression which drives signaling cascades to directly modulate PD-L1 
transcription via NF-κB or IRF-1 promoter elements. (B) PD-L1 expression can be driven by 
STAT-1 or STAT-3 signaling. Type I interferon can signal via the interferon-alpha/beta 
receptor (IFNAR) 1/2 complex to stimulate STAT-1 or -3 homodimerization. Interleukin 6 
and its viral homologue, vIL-6, stimulate STAT-3 homodimerization via the IL-6 receptor 
(IL6R). KSHV infection of monocytes results in increased IFNα and IL-6 protein, and 
presence of vIL-6 message. Thus, KSHV may stimulate PD-L1 indirectly in monocytes via 
paracrine signaling mechanisms.  
 
In addition to direct PD-L1 expression stimulation, KSHV may utilize indirect or 
paracrine mechanisms to increase overall level of PD-L1 (Fig 4.2B). PD-L1 expression can 
be induced by STAT1 or STAT3 signaling (159-161). As mentioned above, both type I and 
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II interferon can stimulate PD-L1 (154-158). IFNγ, a type II interferon, is the most potent and 
best studied inducer of PD-L1. IFNγ induces STAT1 homodimerization, IRF-1 upregulation, 
and PD-L1 expression (156). Interestingly, KSHV infection of monocytes showed PD-L1 
stimulation, but no increase in IFNγ (see Chapter Three) (2). Type I interferon has been 
observed following KSHV infection of human monocytes (see Chapter Three) (2, 72). 
Although type I interferon signaling typically utilizes STAT1 and STAT2 
heterodimerization, STAT1 and STAT3 homodimerization has been demonstrated (206). 
Furthermore, PD-L1 is inducible by type I interferon as mentioned above (see Chapter One). 
KSHV immune stimulation (Fig 4.2A) may drive type I IFN and induce PD-L1 expression in 
uninfected cells via either STAT1 or STAT3 signaling (Fig 4.2B). In addition to IFNα, my 
cytokine screen identified IL-6 increases following KSHV infection in monocytes (see 
Chapter Three) (2). IL-6 ligation of the IL-6 receptor (IL6R) results in STAT3 
homodimerization and is important for PD-L1 expression in tolerogenic antigen presenting 
cells stimulated with TLR ligands (Fig 4.2B) (159). Finally, KSHV encodes a homologue of 
human IL-6, termed viral IL-6 (vIL-6) (3). Following infection of human monocytes, vIL-6 
message can be detected (2). KSHV may utilize vIL-6 to signal through IL6R to 
homodimerize STAT3 and induce PD-L1 expression (Fig 4.2B). Future work could first 
determine the STAT phosphorylation pattern following KSHV infection in monocytes to 
better inform the pathway being utilized. Next, STAT function could be blocked 
pharmacologically to assess involvement in PD-L1 expression following KSHV infection. 
Antibodies could be used to deplete signaling via type I interferon and IL-6 to assess 
involvement. Silencing RNA could be utilized to deplete KSHV produced vIL-6 to determine 
its involvement in PD-L1 in upregulation. In conclusion, PD-L1 is highly likely to be 
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important for KSHV lifecycle and pathogenesis (Fig 4.1). Therefore, it is likely that KSHV 
would utilize multiple routes to ensure its expression, both through direct stimulation during 
infection and via indirect paracrine signaling in naïve cells (Fig 4.2). My work helps set the 
stage for better understanding how KSHV may utilize PD-L1 for its lifecycle and how we 
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